TREATMENT REGIMEN UTILIZING NERATINIB FOR BREAST CANCER

TREATMENT REGIMEN UTILIZING NERATINIB FOR BREAST CANCER

Provided herein is neratinib or a pharmaceutically acceptable salt or hydrate thereof for use in a method for treating HER-2/neu overexpressed/amplified breast cancer in an extended neratinib adjuvant regimen, wherein the method comprises delivering the extended neratinib adjuvant regimen to a HER-2...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: BERKENBLIT, Anna A, GOSS, Paul P, BINLICH, Florence F
Format: Patent
Sprache:chi ; eng
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator BERKENBLIT, Anna A
GOSS, Paul P
BINLICH, Florence F
description Provided herein is neratinib or a pharmaceutically acceptable salt or hydrate thereof for use in a method for treating HER-2/neu overexpressed/amplified breast cancer in an extended neratinib adjuvant regimen, wherein the method comprises delivering the extended neratinib adjuvant regimen to a HER-2/neu overexpressed/amplified breast cancer patient, wherein the extended neratinib adjuvant regimen is started at least 2 weeks, at least one month, at least six months or at least nine months following the completion of a trastuzumab adjuvant therapy, and wherein the extended neratinib adjuvant regimen is administered over a period of at least six months, at least 12 months, at least 18 months, 8 months to 5 years or 12 months to three years; wherein the extended neratinib adjuvant regimen improves invasive disease-free survival (IDFS), disease-free survival - ductal carcinoma in situ (DFS-DCIS), distant disease-free survival (DDFS), and/or time to distant recurrence (TTDR) in the patient.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_HK1223027A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>HK1223027A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_HK1223027A13</originalsourceid><addsrcrecordid>eNrjZDAPCXJ1DPF19QtRCHJ19wQyFEJDPH08ozz93BX8XIMcQzz9PJ0U3PyDFJyAKoNDFJwd_Zxdg3gYWNMSc4pTeaE0N4OCm2uIs4duakF-fGpxQWJyal5qSbyHt6GRkbGBkbmjoTERSgD-3CfO</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>TREATMENT REGIMEN UTILIZING NERATINIB FOR BREAST CANCER</title><source>esp@cenet</source><creator>BERKENBLIT, Anna A ; GOSS, Paul P ; BINLICH, Florence F</creator><creatorcontrib>BERKENBLIT, Anna A ; GOSS, Paul P ; BINLICH, Florence F</creatorcontrib><description>Provided herein is neratinib or a pharmaceutically acceptable salt or hydrate thereof for use in a method for treating HER-2/neu overexpressed/amplified breast cancer in an extended neratinib adjuvant regimen, wherein the method comprises delivering the extended neratinib adjuvant regimen to a HER-2/neu overexpressed/amplified breast cancer patient, wherein the extended neratinib adjuvant regimen is started at least 2 weeks, at least one month, at least six months or at least nine months following the completion of a trastuzumab adjuvant therapy, and wherein the extended neratinib adjuvant regimen is administered over a period of at least six months, at least 12 months, at least 18 months, 8 months to 5 years or 12 months to three years; wherein the extended neratinib adjuvant regimen improves invasive disease-free survival (IDFS), disease-free survival - ductal carcinoma in situ (DFS-DCIS), distant disease-free survival (DDFS), and/or time to distant recurrence (TTDR) in the patient.</description><language>chi ; eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2017</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20170721&amp;DB=EPODOC&amp;CC=HK&amp;NR=1223027A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25563,76318</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20170721&amp;DB=EPODOC&amp;CC=HK&amp;NR=1223027A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>BERKENBLIT, Anna A</creatorcontrib><creatorcontrib>GOSS, Paul P</creatorcontrib><creatorcontrib>BINLICH, Florence F</creatorcontrib><title>TREATMENT REGIMEN UTILIZING NERATINIB FOR BREAST CANCER</title><description>Provided herein is neratinib or a pharmaceutically acceptable salt or hydrate thereof for use in a method for treating HER-2/neu overexpressed/amplified breast cancer in an extended neratinib adjuvant regimen, wherein the method comprises delivering the extended neratinib adjuvant regimen to a HER-2/neu overexpressed/amplified breast cancer patient, wherein the extended neratinib adjuvant regimen is started at least 2 weeks, at least one month, at least six months or at least nine months following the completion of a trastuzumab adjuvant therapy, and wherein the extended neratinib adjuvant regimen is administered over a period of at least six months, at least 12 months, at least 18 months, 8 months to 5 years or 12 months to three years; wherein the extended neratinib adjuvant regimen improves invasive disease-free survival (IDFS), disease-free survival - ductal carcinoma in situ (DFS-DCIS), distant disease-free survival (DDFS), and/or time to distant recurrence (TTDR) in the patient.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2017</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDAPCXJ1DPF19QtRCHJ19wQyFEJDPH08ozz93BX8XIMcQzz9PJ0U3PyDFJyAKoNDFJwd_Zxdg3gYWNMSc4pTeaE0N4OCm2uIs4duakF-fGpxQWJyal5qSbyHt6GRkbGBkbmjoTERSgD-3CfO</recordid><startdate>20170721</startdate><enddate>20170721</enddate><creator>BERKENBLIT, Anna A</creator><creator>GOSS, Paul P</creator><creator>BINLICH, Florence F</creator><scope>EVB</scope></search><sort><creationdate>20170721</creationdate><title>TREATMENT REGIMEN UTILIZING NERATINIB FOR BREAST CANCER</title><author>BERKENBLIT, Anna A ; GOSS, Paul P ; BINLICH, Florence F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_HK1223027A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2017</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>BERKENBLIT, Anna A</creatorcontrib><creatorcontrib>GOSS, Paul P</creatorcontrib><creatorcontrib>BINLICH, Florence F</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>BERKENBLIT, Anna A</au><au>GOSS, Paul P</au><au>BINLICH, Florence F</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>TREATMENT REGIMEN UTILIZING NERATINIB FOR BREAST CANCER</title><date>2017-07-21</date><risdate>2017</risdate><abstract>Provided herein is neratinib or a pharmaceutically acceptable salt or hydrate thereof for use in a method for treating HER-2/neu overexpressed/amplified breast cancer in an extended neratinib adjuvant regimen, wherein the method comprises delivering the extended neratinib adjuvant regimen to a HER-2/neu overexpressed/amplified breast cancer patient, wherein the extended neratinib adjuvant regimen is started at least 2 weeks, at least one month, at least six months or at least nine months following the completion of a trastuzumab adjuvant therapy, and wherein the extended neratinib adjuvant regimen is administered over a period of at least six months, at least 12 months, at least 18 months, 8 months to 5 years or 12 months to three years; wherein the extended neratinib adjuvant regimen improves invasive disease-free survival (IDFS), disease-free survival - ductal carcinoma in situ (DFS-DCIS), distant disease-free survival (DDFS), and/or time to distant recurrence (TTDR) in the patient.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language chi ; eng
recordid cdi_epo_espacenet_HK1223027A1
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title TREATMENT REGIMEN UTILIZING NERATINIB FOR BREAST CANCER
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T22%3A37%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=BERKENBLIT,%20Anna%20A&rft.date=2017-07-21&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EHK1223027A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true